Get the Stockscreener App
0.915
2.15%
-0.0201
Pds Biotechnology Corporation stock is traded at $0.915, with a volume of 239.25K.
It is down -2.15% in the last 24 hours and down -10.29% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$0.9351
Open:
$0.93
24h Volume:
239.25K
Relative Volume:
0.40
Market Cap:
$43.03M
Revenue:
-
Net Income/Loss:
$-40.56M
P/E Ratio:
-0.7821
EPS:
-1.17
Net Cash Flow:
$-35.28M
1W Performance:
-2.00%
1M Performance:
-10.29%
6M Performance:
-33.70%
1Y Performance:
-71.41%
1-Day Range:
$0.915
$0.9505
1-Week Range:
$0.90
$1.16
52-Week Range:
$0.8505
$3.405
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.915 | 43.97M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.07 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.92 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.51 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
810.95 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
180.33 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
Is PDS Biotechnology Corporation stock entering bullish territoryTrade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Portfolio Gains Report & Consistent Income Trade Ideas - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investors2025 Retail Activity & Reliable Trade Execution Plans - newser.com
Will PDS Biotechnology Corporation stock go up soonDividend Hike & Safe Capital Growth Stock Tips - newser.com
Earnings visualization tools for PDS Biotechnology CorporationTrend Reversal & Reliable Trade Execution Plans - newser.com
What machine learning models say about PDS Biotechnology CorporationCPI Data & Fast Moving Trade Plans - newser.com
Is PDS Biotechnology Corporation stock positioned for long term growthJuly 2025 Trends & Safe Capital Growth Tips - newser.com
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval - Stocktwits
Building trade automation scripts for PDS Biotechnology CorporationTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
PDS Biotechnology Seeks Accelerated FDA Pathway for Cancer Therapy - AD HOC NEWS
What dividend safety score for PDS Biotechnology Corporation stockTrade Volume Summary & Fast Moving Market Watchlists - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedRate Hike & Low Drawdown Investment Strategies - newser.com
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces New Clinical and Translational Data on Pds0101 and Pds01adc to Be Presented At the 2025 Society for Immunotherapy of Cancer Annual Meeting - MarketScreener
PDS Biotech to seek expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer - MarketScreener
PDS Biotechnology Corporation Seeks Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Following Promising VERSATILE-002 Trial Results - Quiver Quantitative
PDSB seeks FDA meeting to explore expedited path for PDS0101 - Stock Titan
39.3-month mOS seen with PDS0101 as PDS Biotech (NASDAQ: PDSB) seeks FDA expedited path - Stock Titan
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):